EA201900443A1 - Антитело к pd-l1 и его применение - Google Patents
Антитело к pd-l1 и его применениеInfo
- Publication number
- EA201900443A1 EA201900443A1 EA201900443A EA201900443A EA201900443A1 EA 201900443 A1 EA201900443 A1 EA 201900443A1 EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A EA201900443 A EA 201900443A EA 201900443 A1 EA201900443 A1 EA 201900443A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fully human
- antibodies
- disclosed
- affinity
- lymphocytes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2017028206 | 2017-04-18 | ||
| PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201900443A1 true EA201900443A1 (ru) | 2020-03-06 |
Family
ID=63856823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201900443A EA201900443A1 (ru) | 2017-04-18 | 2018-04-18 | Антитело к pd-l1 и его применение |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20210115143A1 (enExample) |
| EP (1) | EP3612565A4 (enExample) |
| JP (2) | JP2020517239A (enExample) |
| KR (1) | KR102323960B1 (enExample) |
| CN (1) | CN110856446A (enExample) |
| AU (1) | AU2018256392B2 (enExample) |
| BR (1) | BR112019021828B1 (enExample) |
| CA (1) | CA3059447A1 (enExample) |
| CL (1) | CL2019002953A1 (enExample) |
| CO (1) | CO2019012118A2 (enExample) |
| EA (1) | EA201900443A1 (enExample) |
| MA (1) | MA50038A (enExample) |
| MX (1) | MX2019012461A (enExample) |
| MY (1) | MY199319A (enExample) |
| PH (1) | PH12019502302A1 (enExample) |
| SG (1) | SG11201909041SA (enExample) |
| WO (1) | WO2018195226A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| JP7497351B2 (ja) * | 2018-11-13 | 2024-06-10 | コンパス セラピューティクス リミテッド ライアビリティ カンパニー | チェックポイント分子に対する多重特異性結合性構築物およびその使用 |
| CN113646330A (zh) | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
| CA3120096A1 (en) | 2018-11-14 | 2020-05-22 | Rubryc Therapeutics, Inc. | Cd25 antibodies |
| CN109929037B (zh) | 2019-04-01 | 2023-03-17 | 华博生物医药技术（上海）有限公司 | 针对程序性死亡配体的结合物及其应用 |
| JP7302010B2 (ja) * | 2019-04-11 | 2023-07-03 | スクリップス コリア アンチボディ インスティチュート | プログラム細胞死タンパク質リガンド－１（ｐｄ－ｌ１）に対する抗体及びその用途 |
| SG11202103000WA (en) * | 2019-04-26 | 2021-04-29 | I Mab Biopharma Us Ltd | Human pd-l1 antibodies |
| US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| CA3187850A1 (en) | 2020-08-04 | 2022-02-10 | Bryan Glaser | Pd-l1 binding agents and uses thereof |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023046113A1 (zh) * | 2021-09-24 | 2023-03-30 | 广东菲鹏制药股份有限公司 | 一种抗人pd-l1人源化抗体或其抗原结合片段及其应用 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE454137T1 (de) * | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US10202454B2 (en) * | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| WO2015103602A1 (en) * | 2014-01-06 | 2015-07-09 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| CA3265373A1 (en) * | 2014-02-20 | 2025-10-30 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
| MA42971A (fr) * | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| JP7011657B2 (ja) * | 2016-10-30 | 2022-02-10 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗ｐｄ－ｌ１抗体および変異型 |
-
2018
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en not_active Ceased
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en not_active Withdrawn
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko not_active Expired - Fee Related
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en not_active Ceased
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 MY MYPI2019006142A patent/MY199319A/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt not_active IP Right Cessation
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2019012118A2 (es) | 2020-04-01 |
| WO2018195226A1 (en) | 2018-10-25 |
| CL2019002953A1 (es) | 2020-01-10 |
| US20210115143A1 (en) | 2021-04-22 |
| EP3612565A1 (en) | 2020-02-26 |
| CA3059447A1 (en) | 2018-10-25 |
| SG11201909041SA (en) | 2019-11-28 |
| JP2023025003A (ja) | 2023-02-21 |
| BR112019021828B1 (pt) | 2022-09-20 |
| MY199319A (en) | 2023-10-24 |
| EP3612565A4 (en) | 2021-06-16 |
| PH12019502302A1 (en) | 2020-09-21 |
| MX2019012461A (es) | 2019-12-11 |
| AU2018256392B2 (en) | 2024-05-16 |
| BR112019021828A2 (pt) | 2020-03-24 |
| MA50038A (fr) | 2020-07-08 |
| KR20190141169A (ko) | 2019-12-23 |
| JP2020517239A (ja) | 2020-06-18 |
| AU2018256392A1 (en) | 2019-10-17 |
| KR102323960B1 (ko) | 2021-11-10 |
| CN110856446A (zh) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019502302A1 (en) | Anti-pd-l1 antibody and use thereof | |
| EA202092668A1 (ru) | Антитела к ил-11 | |
| JOP20200237B1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
| SA520411173B1 (ar) | Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137 | |
| MX2021003393A (es) | Proteinas de fijacion a sirp alfa y metodos de uso de estas. | |
| EA202091339A1 (ru) | Антитела против cd47 и их применение для лечения онкологических заболеваний | |
| EA202193351A1 (ru) | Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы | |
| MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
| SA523442262B1 (ar) | أجسام مضادة للارتباط بـ cd3 | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MY201526A (en) | Anti-trem2 antibodies and methods of use thereof | |
| NZ704269A (en) | Rspo3 binding agents and uses thereof | |
| EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
| MX360543B (es) | Anticuerpos st-2 humanos solubles y ensayos. | |
| EA201891084A1 (ru) | Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение | |
| MX2022012083A (es) | Moleculas de union de antigeno multiespecificas y usos de las mismas. | |
| NZ612394A (en) | Tnf-α binding proteins | |
| EA201791393A2 (ru) | АНТИТЕЛА К ErbB3 И ИХ ПРИМЕНЕНИЕ | |
| WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
| EA201991704A3 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| PH12019501089A1 (en) | Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same | |
| EA202091974A1 (ru) | Связывающие bcma антитела и их применение | |
| MY202157A (en) | Anti-pd-l1 antibody and use thereof | |
| WO2015112895A3 (en) | Antibody specific to staphylococcus aureus, therapeutic method and detection method using same | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico |